Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Yahoo Finance • 12 days ago

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated s... Full story

Yahoo Finance • 20 days ago

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • 20 days ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Quick Read Easing Iran tensions, strong tech earnings, and a 5% oil price drop drove the Nasdaq up 2% and S&P 500 up 1.5% Monday. Deutsche Bank upgraded PLTR to Buy with a $200 target, while DZ Bank cut AAPL to Hold with a $310 target. Up... Full story

Yahoo Finance • last month

The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures. A single clinical result can send a stock soaring, wipe out years of gains, or threaten the company itself. Drug develo... Full story

Yahoo Finance • 3 months ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today a... Full story

Yahoo Finance • 4 months ago

Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Rezdiffra achieved blockbuster status with over $1.1 billion in trailing 12-month net sales, driven by its position as the firs... Full story

Yahoo Finance • 4 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. fi... Full story

Yahoo Finance • 5 months ago

Noteworthy Tuesday Option Activity: WSBF, MDGL, NKE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Waterstone Financial Inc (Symbol: WSBF), where a total volume of 724 contracts has been traded thus far today, a contract... Full story

Yahoo Finance • 5 months ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 5 months ago

Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug

Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following positive news about corporate earnings... Full story

Yahoo Finance • 5 months ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 5 months ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 5 months ago

What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 20, Bank of America Securities lowered the price target on Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) f... Full story

Yahoo Finance • 6 months ago

MKKGY or MDGL: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Merck KGaA (MKKGY) or Madrigal (MDGL). But which of these two stocks presents investors with the better value opportunity right now? Let's take a clos... Full story

Yahoo Finance • 8 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 8 months ago

2 Predictions for Novo Nordisk in 2026

Key Points Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo Nordisk's shares appear attrac... Full story

Yahoo Finance • 9 months ago

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story

Yahoo Finance • 9 months ago

Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains... Full story

Yahoo Finance • 9 months ago

Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to rally in the third quarter, the period w... Full story

Yahoo Finance • 9 months ago

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare C... Full story